Long acting GLP-1 receptor agonist (injectable)
Albiglutide 30 mg subcutaneous once weekly
ALBI_SC_30MG_QW
Withdrawn from the market in 2018 for commercial reasons.
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.28 (-1.76 to -0.47) | 0.53 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.07 (-2.00 to 0.61) | 0.49 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.83 (-1.80 to 0.31) | 0.26 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.22 (-2.39 to 5.88) | 0.26 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 2.11 (-3.46 to 7.78) | 0.25 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 0.30 (-4.85 to 5.03) | 0.14 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 10.32 (2.15 to 37.66) | 0.64 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 3.25 (0.83 to 10.41) | 0.48 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 2.94 (0.34 to 12.47) | 0.33 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.53 (0.01 to 36.13) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.31 (0.51 to 3.22) | 0.53 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.55 (0.87 to 2.72) | 0.28 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.53 (0.36 to 6.51) | 0.51 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.35 (0.73 to 2.45) | 0.72 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.58 (0.90 to 7.02) | 0.51 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.82 (0.46 to 1.46) | 0.77 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.65 (0.72 to 3.72) | 0.50 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.77 (0.05 to 11.03) | 0.50 |
Trials
- NCT01733758A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus2013 · 494 randomized · 52 weeks
- NCT00849017A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus2009 · 309 randomized · 156 weeks
- NCT00518115A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, With Byetta as an Open Label Active Reference, in Subjects With Type 2 Diabetes Mellitus2007 · 361 randomized · 16 weeks